Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF4E | P06730 | 2/20 | 0.61 |
| ▸ | EIF4EBP1 | Q13541 | 2/20 | 0.61 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.54 |
| ▸ | ESR1 | P03372 | 6/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.51 |
| ▸ | KRAS | P01116 | 6/20 | 0.45 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.45 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.45 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.45 |
| ▸ | PRKAR2A | P13861 | 1/20 | 0.44 |
| ▸ | PRKAR2B | P31323 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26420961 | 0.94 | EIF4E (0.61) | EIF4EEIF4EBP1ACE2ESR1ESR2 | |
| SCHEMBL20694359 | 0.92 | EIF4E (0.56) | EIF4EEIF4EBP1ACE2ESR1ESR2 | |
| SCHEMBL24919277 | 0.81 | ESR1 (0.53) | EIF4EEIF4EBP1ACE2ESR1ESR2 | |
| SCHEMBL22802819 | 0.76 | ESR1 (0.51) | EIF4EEIF4EBP1ACE2ESR1ESR2 | |
| SCHEMBL20694604 | 0.70 | ESR1 (0.52) | EIF4EEIF4EBP1ACE2ESR1ESR2 | |
| SCHEMBL24473539 | 0.67 | NTSR2 (0.61) | EIF4EEIF4EBP1ACE2ESR1ESR2 | |
| SCHEMBL24473602 | 0.67 | NTSR2 (0.71) | EIF4EEIF4EBP1PRKAR2APRKAR2B | |
| SCHEMBL24473663 | 0.66 | NTSR2 (0.61) | EIF4EEIF4EBP1ACE2PRKAR2APRKAR2B | |
| SCHEMBL20694606 | 0.66 | ESR1 (0.51) | ACE2ESR1ESR2KRASNFE2L2 | |
| SCHEMBL24473339 | 0.65 | NTSR2 (0.73) | EIF4EEIF4EBP1PRKAR2APRKAR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230330240-A1 | TECHNOLOGIES FOR PREVENTING OR TREATING INFECTIONS | BIOHAVEN THERAPEUTICS LTD (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230028880-A1 | CD38-BINDING AGENTS AND USES THEREOF | KLEO PHARMACEUTICALS, INC. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230028880-A1 | CD38-BINDING AGENTS AND USES THEREOF | CD38, CD47, CD2 | EIF4E 4800/4885EIF4EBP1 4112/4885ACE2 2123/4885 |
| US-20230330240-A1 | TECHNOLOGIES FOR PREVENTING OR TREATING INFECTIONS | HAVCR2, ACE2, EPCAM | EIF4E 684/4885EIF4EBP1 883/4885ACE2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.